Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

Summary

The purpose of this first in human and proof of concept study is to characterize the safety, tolerability and initial efficacy of CLL442 in patients with Squamous Cell Carcinoma in situ (SCCis) to enable further clinical development of CLL442.

Timeline

Start

2017-12-15

Primary completion

2018-11-01

Completion

2018-11-01

Outcome

Outcome not reported

Stopped (Enrollment): “The study fully enrolled and completed after last patient completed the study”

Drugs

Indications